Welcome to the REVEAL Study website

The REVEAL study is an international clinical trial that aims to find out if treating cholesterol with a new drug called anacetrapib will drive down the risk of heart attacks, deaths from heart disease and other vascular diseases.

What does the REVEAL study involve?

• REVEAL will involve over 30,000 men and women who already have some form of circulatory disease.
• Participants will be recruited from the UK, North America, China, Germany, Italy and Scandinavia.
• All study participants will be given atorvastatin (a commonly used "statin" drug) to ensure good control of LDL ("bad") cholesterol.
• Participants will also receive either anacetrapib or matching placebo (dummy) tablets daily (allocated randomly).
• The study will continue for at least four years.
• The primary aim of the study is to see whether fewer participants given anacetrapib have heart attacks, revascularization procedures or die from coronary heart disease than do those given the placebo tablets.

Who is responsible for the REVEAL study?

The study is being coordinated by the Clinical Trial Service Unit (CTSU) at Oxford University.

Further Information

We are in the process of updating these pages.

In the meantime, if you would like further information, please contact us on 0800 585323 or email reveal@ctsu.ox.ac.uk